TY - JOUR
T1 - Complications of prostate biopsy
AU - Anastasiadis, Anastasios
AU - Zapała, Lukasz
AU - Cordeiro, Ernesto
AU - Antoniewicz, Artur
AU - Dimitriadis, Georgios
AU - de Reijke, Theo
PY - 2013
Y1 - 2013
N2 - Biopsy of the prostate is a common procedure with minor complications that are usually self-limited. However, if one considers that millions of men undergo biopsy worldwide, one realizes that although complication rate is low, the number of patients suffering from biopsy complications should not be underestimated and can be a clinically relevant problem for healthcare professionals. In this review, the authors present diagnosis and management of postbiopsy of prostate complications. Bleeding is the most common complication observed after prostate biopsy, but the use of aspirin or nonsteroidal anti-inflammatory drugs is not an absolute contraindication to prostate biopsy. Emerging resistance to ciprofloxacin is the most probable cause of the increasing risk of infectious complications after prostate biopsy. Even though extremely rare, fatal complications are possible and were described in case reports
AB - Biopsy of the prostate is a common procedure with minor complications that are usually self-limited. However, if one considers that millions of men undergo biopsy worldwide, one realizes that although complication rate is low, the number of patients suffering from biopsy complications should not be underestimated and can be a clinically relevant problem for healthcare professionals. In this review, the authors present diagnosis and management of postbiopsy of prostate complications. Bleeding is the most common complication observed after prostate biopsy, but the use of aspirin or nonsteroidal anti-inflammatory drugs is not an absolute contraindication to prostate biopsy. Emerging resistance to ciprofloxacin is the most probable cause of the increasing risk of infectious complications after prostate biopsy. Even though extremely rare, fatal complications are possible and were described in case reports
U2 - https://doi.org/10.1586/14737140.2013.811056
DO - https://doi.org/10.1586/14737140.2013.811056
M3 - Review article
C2 - 23875661
SN - 1473-7140
VL - 13
SP - 829
EP - 837
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 7
ER -